LRMR
Larimar Therapeutics Inc.
$5.04
$0.00(0.00%)
55
Overall
60
Value
50
Tech
--
Quality
Market Cap
$292.72M
Volume
1.08M
52W Range
$1.61 - $6.42
Target Price
$16.70
Company Overview
| Mkt Cap | $292.72M | Price | $5.04 |
| Volume | 1.08M | Change | +0.00% |
| P/E Ratio | -3.6 | Open | $4.99 |
| Revenue | -- | Prev Close | $5.04 |
| Net Income | $-80.6M | 52W Range | $1.61 - $6.42 |
| Div Yield | N/A | Target | $16.70 |
| Overall | 55 | Value | 60 |
| Quality | -- | Technical | 50 |
No chart data available
About Larimar Therapeutics Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Larimar Therapeutics (LRMR) and Eli Lilly & Co (LLY)
Catie Powers•19 days ago
Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)
TipRanks Auto-Generated Intelligence Newsdesk•19 days ago
Larimar Advances Nomlabofusp Toward 2026 BLA Submission
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LRMR | $5.04 | 0% | 1.08M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Larimar Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW